[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588813":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":27,"responsibleParty":46,"collaborators":11,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":11,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":11,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":11,"overallStatus":69,"whyStopped":11,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"China International Neuroscience Institution","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Dexmedetomidine Preemptive Analgesia","EXPERIMENTAL",null,[13],"Drug: Preemptive Analgesia Of Dexmedetomidine",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","Preemptive Analgesia Of Dexmedetomidine","Preemptive Analgesia Of Dexmedetomidine 1.5 μg · kg-1·h-1 before operation",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},"Yanghai Cui, prof","CONTACT","+861083199270","+8618196987786","1055885750@qq.com",[28],{"facility":29,"status":11,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Xuanwu hospital","Beijing","Beijing Municipality","100053","China","CN",{"type":36,"coordinates":37},"Point",[38,39],116.39723,39.9075,{"lat":39,"lon":38},[42],{"name":43,"role":23,"phone":44,"phoneExt":45,"email":26},"Yanghai Cui, PHD","83199270","15010283592",{"type":47,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100588813","phase-4-assessing-the-time-course-of-dexmedetomidine-induced-analgesia-via-eeg-100588813",false,"NCT06946277","Assessing the Time-Course of Dexmedetomidine-Induced Analgesia Via EEG","Mapping the Temporal Profile of Dexmedetomidine-Induced Analgesia Via EEG Signatures in Brain","Inclusion Criteria:\n\nPatients with hip osteoarthritis scheduled for total hip arthroplasty under intrathecal anesthesia; Age 18-70 years; American Society of Anesthesiologists (ASA) physical status classification I-III; Body mass index (BMI) 22-30 kg\u002Fm².\n\nExclusion Criteria:\n\nPre-existing peripheral or central nervous system disorders; Mental disorders; Cognitive impairment; Emergency surgery; or Hearing impairment.","ALL","18 Years","70 Years",{"count":59,"type":60},20,"ESTIMATED","INTERVENTIONAL",[63],"PHASE4","Objective: To investigate the temporal dynamics of dexmedetomidine's analgesic effects in the brain using EEG.\n\nMethods: Eligible patients scheduled for total hip arthroplasty under intrathecal anesthesia received a continuous infusion of DEX at 1.5 μg\u002F(kg·h) for 15 minutes before neuraxial puncture, followed by an additional 15-minute infusion. The study was divided into three phases:\n\nPhase 1: Non-dosing phase (Baseline). Phase 2: DEX preemptive analgesia phase (DEX infusion). Phase 3: DEX cessation phase (Post-infusion).\n\nOutcomes:\n\nPrimary safety outcome: EEG spectral analysis at different phases. Secondary outcomes: NRS scores, postoperative nausea and vomiting (PONV), dizziness, agitation, and time to intestinal exhaust within 48 hours. Intraoperative hemodynamics were also monitored.",[66,67,68],"Total Hip Arthroplasty (THA)","Intrathecal Anesthesia","Hip Osteoarthritis","NOT_YET_RECRUITING","2025-04-23",{"date":72,"type":73},"2025-04-27","ACTUAL",{"date":75,"type":60},"2025-04-25",{"date":77,"type":60},"2025-05-26",{"name":5,"class":6},1]